 Avalon GloboCare Corp NASDAQ:AVCO said it will collaborate with the University of Pittsburgh Medical Center UPMC Hillman Cancer Center to advance the companys AVA-011 therapy and other RNA-based candidates. AVA-011 targets tumor antigens on cancer cells and is being developed for patients with relapsedrefractory B-cell lymphoblastic leukemia and non-Hodgkins lymphoma ahead of the first human clinical trials. 